Tokyo, June 12, 2007 (JCN Newswire) - Kissei Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced the conclusion of a license agreement for Glufast(R) (tablets, generic name: mitiglinide calcium hydrate), a rapid-acting insulin secretagogue originally created and developed by Kissei. In this agreement, Eisai gained the exclusive development and commercialization rights of Glufast(R) in a total of 10 ASEAN countries from Kissei.
